2. Search Result
Search Result
Results for "

Antiarrhythmic effect

" in MedChemExpress (MCE) Product Catalog:

42

Inhibitors & Agonists

1

Peptides

7

Natural
Products

6

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-108586
    NS3623

    		Potassium Channel Neurological Disease
    NS3623 is an activator of human ether-a-go-go-related gene (hERG1/KV11.1) potassium channels. NS3623 activates the IKr and Ito currents and has antiarrhythmic effect. NS3623 has a dual mode of action, being an inhibitor of hERG1 channels .
    NS3623
  • HY-10913A
    Danegaptide Hydrochloride
    1 Publications Verification

    GAP-134 Hydrochloride; ZP 1609 Hydrochloride

    		 Gap Junction Protein Cardiovascular Disease
    Danegaptide Hydrochloride (GAP-134 Hydrochloride) is a potent, selective and orally active gap-junction modifier with an antiarrhythmic effect .
    Danegaptide Hydrochloride
  • HY-116119
    BDF 9148

    		Sodium Channel Cardiovascular Disease
    BDF 9148 is a sodium-channel activator with antiarrhythmic properties that produces a significant CAMP-independent positive inotropic effect in left ventricular myocardium from failing hearts. BDF 9148 is promising for research of myocardial failure .
    BDF 9148
  • HY-176305S
    Neurofilament, U-15N

    		Isotope-Labeled Compounds Neurological Disease
    Neurofilament, U- 15N is the 15N-labeled Neurofilament.
    Neurofilament, U-15N
  • HY-117471
    Antiarrhythmic agent-3

    		Endogenous Metabolite Neurological Disease
    Antiarrhythmic agent-3 is an antiarrhythmic drug with the activity of enhancing antiarrhythmic efficacy and improving inhibition index. The antiarrhythmic effect of antiarrhythmic agent-3 is related to its hydrophobicity (log P). The central nervous system toxicity of antiarrhythmic agent-3 is related to the combined effect of its hydrophobicity and acid constant (pKa) .
    Antiarrhythmic agent-3
  • HY-169624
    GPV574

    		Potassium Channel Cardiovascular Disease
    GPV574 is a derivative of the antiarrhythmic compound propafenone, capable of inhibiting HERG channels (IC50 = 5.04 μM).
    GPV574
  • HY-10913
    Danegaptide

    GAP-134; ZP 1609

    		 Gap Junction Protein Cardiovascular Disease
    Danegaptide (GAP-134) is a potent, selective and orally active gap-junction modifier with an antiarrhythmic effect .
    Danegaptide
  • HY-115839A
    Detajmium L-tartrate

    Detajmium bitartrate; Tachmalcor

    		 Sodium Channel Cardiovascular Disease
    Detajmium (L-tartrate) is an antiarrhythmic compound. Detajmium has effect on V max in both dog ventricular muscle and Purkinje fibers was frequency dependent .
    Detajmium L-tartrate
  • HY-122364
    Bucumolol hydrochloride

    		Adrenergic Receptor Cardiovascular Disease
    Bucumolol hydrochloride is a β-adrenergic receptor antagonist that can slow heart rate (negative chronotropic effect) and reduce cardiac contractility (negative inotropic effect). Bucumolol hydrochloride has antiarrhythmic and local anesthetic activity and can be used in the study of cardiovascular diseases .
    Bucumolol hydrochloride
  • HY-119092
    Bisaramil

    		Sodium Channel Cardiovascular Disease
    Bisaramil is an orally active antiarrhythmic agent. Bisaramil exerts concentration dependent inhibitory effect on PMA-stimulated free radical generation and prolonged the time lag concentration dependently .
    Bisaramil
  • HY-101205
    ICI 199441

    		Opioid Receptor Cardiovascular Disease
    ICI 199441 is a potent and selective κ-opioid receptor agonist. ICI 199441 can improve heart resistance to ischemia/reperfusion .
    ICI 199441
  • HY-N6772R
    Cytochalasin E (Standard)

    		Reference Standards Autophagy Cancer
    Antazoline (phosphate) (Standard) is the analytical standard of Antazoline (phosphate). This product is intended for research and analytical applications. Antazoline phosphate is an H1 receptor antagonist that affects the activity of the central nervous system, has a potent antiarrhythmic effect .
    Cytochalasin E (Standard)
  • HY-B1167A
    Ajmaline hydrochloride

    Cardiorythmine hydrochloride; (+)-Ajmaline hydrochloride

    		 Others Cardiovascular Disease
    Ajmaline hydrochloride is a Class Ia antiarrhythmic agent. It inhibits HERG potassium channels with IC50s of 1.0 μmol/l and 42.3 μmol/l in HEK cells and moth spider oocytes respectively. The inhibitory effect of Ajmaline hydrochloride is rapid, reversible, and positive frequency dependent. It acts primarily on the open state of the HERG channel and may also be combined with the inactivated state. The inhibitory effect of ajmaline hydrochloride is dependent on aromatic residues in the S6 domain, and the sensitivity is significantly reduced in the inactivation-deficient HERG S620T channel. It can also slightly affect the activation voltage of HERG channels. Ajmaline hydrochloride's inhibitory effect on HERG channels may contribute to both its potent antiarrhythmic effects and its potential proarrhythmic risk.
    Ajmaline hydrochloride
  • HY-B1067B
    Antazoline phosphate

    Phenazoline phosphate

    		 Histamine Receptor Neurological Disease Endocrinology
    Antazoline phosphate is an H1 receptor antagonist that affects the activity of the central nervous system, has a potent antiarrhythmic effect . Antazoline phosphate is a histamine H1 receptor antagonist with anticholinergic and antiviral properties. Antazoline phosphate can prevent histamine from acting on target cells through a reversible competition effect on histamine receptor sites of these cells. Antazoline phosphate can exert an antiallegic effect and prevent the occurrence of physiological reactions from the effect of blocking as well as inhibiting H1 receptor. Antazoline phosphate can effectively reduce HBV DNA in the extracellular supernatant in a dose-dependent manner, with EC50 of 2.910 μmol/L in HepAD38 cells. Antazoline phosphate also has a significant inhibitory effect on HBV DNA in the extracellular supernatant of Huh7 cells (EC50 = 2.349 μmol/L). Antazoline phosphate has anti-arrhythmic effect in acute myocardial infarctions. Antazoline phosphate can be studied in research for cardiovascular diseases, and HBV .
    Antazoline phosphate
  • HY-123785
    ORM-10962
    1 Publications Verification

    		 Na+/Ca2+ Exchanger Metabolic Disease
    ORM-10962 is a potent, highly selective sodium-calcium exchanger (NCX) inhibitor, with IC50 values of 67 and 55 nM for the reverse and forward mode inhibition, respectively. ORM-10962 shows antiarrhythmic effect .
    ORM-10962
  • HY-N0221
    Daurisoline
    4 Publications Verification

    (R,R)-Daurisoline

    		 Autophagy Potassium Channel Cancer
    Daurisoline is a bis-benzylisoquinoline alkaloid that can be isolated from Menispermum dauricum and Rhizoma Menispermi. Daurisoline exerts a blocking effect on hERG and has antiarrhythmic effects. Daurisoline is a potent autophagy blocker that can be used for the research of cancer .
    Daurisoline
  • HY-10913S
    Danegaptide-d5

    GAP-134-d5; ZP 1609-d5

    		 Isotope-Labeled Compounds Gap Junction Protein Cardiovascular Disease
    Danegaptide-d5 (GAP-134-d5) is deuterium labeled Danegaptide. Danegaptide (GAP-134) is a potent, selective and orally active gap-junction modifier with an antiarrhythmic effect .
    Danegaptide-d5
  • HY-N2255
    Crebanine
    1 Publications Verification

    		 Akt Apoptosis Cardiovascular Disease Inflammation/Immunology Cancer
    Crebanine, an alkaloid from Stephania venosa, induces G1 arrest and apoptosis in human cancer cells. Crebanine exhibits anti-inflammatory activity via suppressing MAPKs and Akt signaling. Crebanine also possesses antiarrhythmic effect .
    Crebanine
  • HY-126704
    Tedisamil

    KC-8857

    		 Potassium Channel Cardiovascular Disease
    Tedisamil (KC-8857) is an antiarrhythmic compound with important biological activities. Tedisamil exhibits a significant slowing effect on heart rate, which is achieved by inhibiting the transient outward potassium current (I(to)) in the atrium. Tedisamil inhibits multiple potassium currents, including IK, K(ATP), and PKA-activated chloride channels, thereby prolonging the cardiac action potential and QT interval, and increasing cardiac reentry. Tedisamil has antiarrhythmic effects on ventricular arrhythmias and atrial flutter in animal models .
    Tedisamil
  • HY-156976A
    Sulcardine hydrochloride

    		Calcium Channel Sodium Channel Cardiovascular Disease
    Sulcardine hydrochloride is a multi-ion channel blocker that can reduce INa and ICa with IC50 values of 26.9 µM and 69.2 µM, respectively. Sulcardine hydrochloride is a potent hNav1.5 channel blocker with a mild inhibitory effect on hERG channels. Sulcardine hydrochloride has anti-arrhythmic effects .
    Sulcardine hydrochloride
  • HY-156976
    Sulcardine

    		Calcium Channel Sodium Channel Cardiovascular Disease
    Sulcardine is a multi-ion channel blocker that can reduce INa and ICa with IC50 values of 26.9 µM and 69.2 µM, respectively. Sulcardine is a potent hNav1.5 channel blocker with a mild inhibitory effect on hERG channels. Sulcardine has anti-arrhythmic effects .
    Sulcardine
  • HY-N0221R
    Daurisoline (Standard)

    		Autophagy Potassium Channel Cancer
    Daurisoline (Standard) is the analytical standard of Daurisoline. This product is intended for research and analytical applications. Daurisoline is a bis-benzylisoquinoline alkaloid that can be isolated from Menispermum dauricum and Rhizoma Menispermi. Daurisoline exerts a blocking effect on hERG and has antiarrhythmic effects. Daurisoline is a potent autophagy blocker that can be used for the research of cancer .
    Daurisoline (Standard)
  • HY-N0221S
    Daurisoline-d2

    (R,R)-Daurisoline-d2

    		 Isotope-Labeled Compounds Potassium Channel Autophagy Cancer
    Daurisoline-d2 is the deuterium labeled Daurisoline (HY-N0221). Daurisoline is a bis-benzylisoquinoline alkaloid that can be isolated from Menispermum dauricum and Rhizoma Menispermi. Daurisoline exerts a blocking effect on hERG and has antiarrhythmic effects. Daurisoline is a potent autophagy blocker that can be used for the research of cancer .
    Daurisoline-d2
  • HY-N2106
    Dehydroevodiamine
    1 Publications Verification

    		 NF-κB COX PGE synthase NO Synthase Inflammation/Immunology
    Dehydroevodiamine is a major bioactive quinazoline alkaloid isolated from Evodiae Fructus, has an antiarrhythmic effect in guinea-pig ventricular myocytes . Dehydroevodiamine inhibits LPS-induced iNOS, COX-2, prostaglandin E2 (PGE2) and nuclear factor-kappa B (NF-κB) expression in murine macrophage cells .
    Dehydroevodiamine
  • HY-N0221S2
    Daurisoline-d11

    (R,R)-Daurisoline-d11

    		 Isotope-Labeled Compounds Potassium Channel Autophagy Cancer
    Daurisoline-d11 is the deuterium labeled Daurisoline (HY-N0221). Daurisoline is a bis-benzylisoquinoline alkaloid that can be isolated from Menispermum dauricum and Rhizoma Menispermi. Daurisoline exerts a blocking effect on hERG and has antiarrhythmic effects. Daurisoline is a potent autophagy blocker that can be used for the research of cancer .
    Daurisoline-d11
  • HY-144801A
    DDO-02005

    		Potassium Channel Cardiovascular Disease
    DDO-02005 is a potent Kv1.5 potassium channel inhibitor with an IC50 value of 0.72 μM. DDO-02005 has good anti-atrial fibrillation (AF) effect in CaCl2-ACh AF rats model and effective anti-arrhythmic activity caused by aconitine .
    DDO-02005
  • HY-N0221S1
    Daurisoline-d5

    (R,R)-Daurisoline-d5

    		 Isotope-Labeled Compounds Potassium Channel Autophagy Cancer
    Daurisoline-d5 is the deuterium labeled Daurisoline (HY-N0221). Daurisoline is a bis-benzylisoquinoline alkaloid that can be isolated from Menispermum dauricum and Rhizoma Menispermi. Daurisoline exerts a blocking effect on hERG and has antiarrhythmic effects. Daurisoline is a potent autophagy blocker that can be used for the research of cancer .
    Daurisoline-d5
  • HY-B1067
    Antazoline hydrochloride

    Phenazoline hydrochloride

    		 Histamine Receptor HBV Neurological Disease Endocrinology
    Antazoline hydrochloride is a histamine H1 receptor antagonist with anticholinergic and antiviral properties. Antazoline hydrochloride can prevent histamine from acting on target cells through a reversible competition effect on histamine receptor sites of these cells. Antazoline hydrochloride can exert an antiallegic effect and prevent the occurrence of physiological reactions from the effect of blocking as well as inhibiting H1 receptor. Antazoline hydrochloride can effectively reduce HBV DNA in the extracellular supernatant in a dose-dependent manner, with EC50 of 2.910 μmol/L in HepAD38 cells. Antazoline hydrochloride also has a significant inhibitory effect on HBV DNA in the extracellular supernatant of Huh7 cells (EC50 = 2.349 μmol/L). Antazoline hydrochloride has anti-arrhythmic effect in acute myocardial infarctions. Antazoline hydrochloride can be studied in research for cardiovascular diseases, and HBV .
    Antazoline hydrochloride
  • HY-144801
    DDO-02005 free base

    		Potassium Channel Cardiovascular Disease
    DDO-02005 (free base) is a potent Kv1.5 potassium channel inhibitor with an IC50 value of 0.72 μM. DDO-02005 (free base) has good anti-atrial fibrillation (AF) effect in CaCl2-ACh AF rats model and effective anti-arrhythmic activity caused by aconitine .
    DDO-02005 free base
  • HY-B1067A
    Antazoline

    Phenazoline

    		 Histamine Receptor Neurological Disease Endocrinology
    Antazoline (Phenazoline) is a histamine H1 receptor antagonist with anticholinergic and antiviral properties. Antazoline can prevent histamine from acting on target cells through a reversible competition effect on histamine receptor sites of these cells. Antazoline can exert an antiallegic effect and prevent the occurrence of physiological reactions from the effect of blocking as well as inhibiting H1 receptor. Antazoline can effectively reduce HBV DNA in the extracellular supernatant in a dose-dependent manner, with EC50 of 2.910 μmol/L in HepAD38 cells. Antazoline also has a significant inhibitory effect on HBV DNA in the extracellular supernatant of Huh7 cells (EC50 = 2.349 μmol/L). Antazoline has anti-arrhythmic effect in acute myocardial infarctions. Antazoline can be studied in research for cardiovascular diseases, and HBV .
    Antazoline
  • HY-N3289A
    (E)-Methyl 3,4,5-trimethoxycinnamate

    		Others Inflammation/Immunology
    (E)-Methyl 3,4,5-trimethoxycinnamate is a bioactive natural phenylpropanoid. (E)-Methyl 3,4,5-trimethoxycinnamate suppresses inflammation in RAW264.7 macrophages and blocks macrophage-adipocyte interaction. (E)-Methyl 3,4,5-trimethoxycinnamate also has antiarrhythmic effect, leads to suppression of triggered activities in rabbit myocytes .
    (E)-Methyl 3,4,5-trimethoxycinnamate
  • HY-120355
    AP14145

    		Potassium Channel Cardiovascular Disease
    AP14145 is an inhibitor for small conductance calcium-activated potassium channel, inhibits KCa2.2 channel and KCa channel with IC50 of 1.1 μM and 1.1 μM. AP14145 prolongs atrial effective refractory period (AERP) in rats, causes the conversion of atrial fibrillation to sinus rhythum in porcine left ventricular dysfunction models, and exhibits antiarrhythmic effect .
    AP14145
  • HY-B1067AR
    Antazoline (Standard)

    Phenazoline (Standard)

    		 Reference Standards Histamine Receptor Neurological Disease Endocrinology
    Antazoline (Phenazoline) (Standard) is the analytical standard of Antazoline. This product is intended for research and analytical applications. Antazoline is a histamine H1 receptor antagonist with anticholinergic and antiviral properties. Antazoline can prevent histamine from acting on target cells through a reversible competition effect on histamine receptor sites of these cells. Antazoline can exert an antiallegic effect and prevent the occurrence of physiological reactions from the effect of blocking as well as inhibiting H1 receptor. Antazoline can effectively reduce HBV DNA in the extracellular supernatant in a dose-dependent manner, with EC50 of 2.910 μmol/L in HepAD38 cells. Antazoline also has a significant inhibitory effect on HBV DNA in the extracellular supernatant of Huh7 cells (EC50 = 2.349 μmol/L). Antazoline has anti-arrhythmic effect in acute myocardial infarctions. Antazoline can be studied in research for cardiovascular diseases, and HBV .
    Antazoline (Standard)
  • HY-B1067R
    Antazoline hydrochloride (Standard)

    Phenazoline hydrochloride (Standard)

    		 Reference Standards Histamine Receptor HBV Neurological Disease Endocrinology
    Antazoline (hydrochloride) (Standard) is the analytical standard of Antazoline (hydrochloride). This product is intended for research and analytical applications. Antazoline hydrochloride is a histamine H1 receptor antagonist with anticholinergic and antiviral properties. Antazoline hydrochloride can prevent histamine from acting on target cells through a reversible competition effect on histamine receptor sites of these cells. Antazoline hydrochloride can exert an antiallegic effect and prevent the occurrence of physiological reactions from the effect of blocking as well as inhibiting H1 receptor. Antazoline hydrochloride can effectively reduce HBV DNA in the extracellular supernatant in a dose-dependent manner, with EC50 of 2.910 μmol/L in HepAD38 cells. Antazoline hydrochloride also has a significant inhibitory effect on HBV DNA in the extracellular supernatant of Huh7 cells (EC50 = 2.349 μmol/L). Antazoline hydrochloride has anti-arrhythmic effect in acute myocardial infarctions. Antazoline hydrochloride can be studied in research for cardiovascular diseases, and HBV .
    Antazoline hydrochloride (Standard)
  • HY-B1067BR
    Antazoline phosphate (Standard)

    Phenazoline phosphate (Standard)

    		 Reference Standards Histamine Receptor Neurological Disease Endocrinology
    Antazoline (phosphate) (Standard) is the analytical standard of Antazoline (phosphate). This product is intended for research and analytical applications. Antazoline phosphate is a histamine H1 receptor antagonist with anticholinergic and antiviral properties. Antazoline phosphate can prevent histamine from acting on target cells through a reversible competition effect on histamine receptor sites of these cells. Antazoline phosphate can exert an antiallegic effect and prevent the occurrence of physiological reactions from the effect of blocking as well as inhibiting H1 receptor. Antazoline phosphate can effectively reduce HBV DNA in the extracellular supernatant in a dose-dependent manner, with EC50 of 2.910 μmol/L in HepAD38 cells. Antazoline phosphate also has a significant inhibitory effect on HBV DNA in the extracellular supernatant of Huh7 cells (EC50 = 2.349 μmol/L). Antazoline phosphate has anti-arrhythmic effect in acute myocardial infarctions. Antazoline phosphate can be studied in research for cardiovascular diseases, and HBV .
    Antazoline phosphate (Standard)
  • HY-B1392A
    Esmolol

    		Adrenergic Receptor Caspase Apoptosis Aldose Reductase Neurokinin Receptor Cardiovascular Disease Endocrinology Cancer
    Esmolol is an ultra-short-acting cardioselective β1-adrenergic blocker. Esmolol exerts its antiarrhythmic effect by activating Neurokinin 1 Receptor. Esmolol attenuates post resuscitation myocardial dysfunction. Esmolol improves diabetic wound healing by inhibiting aldose reductase and the production of advanced glycation end products and promoting fibroblast migration. Esmolol can be used to study cardiac diseases such as arrhythmias and diabetic foot ulcers .
    Esmolol
  • HY-101607A
    KT-362 free acid

    		Calcium Channel Cardiovascular Disease
    KT-362 free acid is an intracellular calcium antagonist with antiarrhythmic and vasodilatory effects. KT-362 free acid shows an antagonistic effect against norepinephrine (NE) induced vasoconstriction response, achieved by reducing inositol phospholipid hydrolysis, thereby reducing intracellular calcium mobilization. KT-362 free acid can be used to study the contraction and relaxation mechanisms of vascular smooth muscle, especially in exploring the role of intracellular calcium mobilization and inositol phospholipid hydrolysis in vascular contraction .
    KT-362 free acid
  • HY-B1392
    Esmolol hydrochloride
    3 Publications Verification

    		 Adrenergic Receptor Caspase Apoptosis Aldose Reductase Neurokinin Receptor Cardiovascular Disease Endocrinology Cancer
    Esmolol hydrochloride is an ultra-short-acting cardioselective β1-adrenergic blocker. Esmolol hydrochloride exerts its antiarrhythmic effect by activating Neurokinin 1 Receptor. Esmolol hydrochloride attenuates post resuscitation myocardial dysfunction. Esmolol hydrochloride improves diabetic wound healing by inhibiting aldose reductase and the production of advanced glycation end products and promoting fibroblast migration. Esmolol hydrochloride can be used to study cardiac diseases such as arrhythmias and diabetic foot ulcers .
    Esmolol hydrochloride
  • HY-103160B
    EHNA

    		Adenosine Deaminase Phosphodiesterase (PDE) Influenza Virus Infection Cardiovascular Disease Neurological Disease Cancer
    EHNA is a potent and selective dual inhibitor of cyclic nucleotide phosphodiesterase 2 (PDE2)(IC50=4 μM) and adenosine deaminase (ADA). EHNA exerts a concentration inhibition of the cGMP-stimulated PDE II (cGs-PDE)(IC50:0.8 μM (human), 2 μM (porcine myocardium)), but has smaller inhibitory effect on the unstimulated PDE2 activity. EHNA play roles in mediating diverse pharmacological responses, including antiviral, antitumour and antiarrhythmic effects .
    EHNA
  • HY-103160A
    EHNA hydrochloride
    4 Publications Verification

    		 Adenosine Deaminase Phosphodiesterase (PDE) Influenza Virus Infection Cardiovascular Disease Neurological Disease Cancer
    EHNA hydrochloride is a potent and selective dual inhibitor of cyclic nucleotide phosphodiesterase 2 (PDE2)(IC50=4 μM) and adenosine deaminase (ADA). EHNA hydrochloride exerts a concentration inhibition of the cGMP-stimulated PDE II (cGs-PDE)(IC50:0.8 μM (human), 2 μM (porcine myocardium)), but has smaller inhibitory effect on the unstimulated PDE2 activity. EHNA hydrochloride play roles in mediating diverse pharmacological responses, including antiviral, antitumour and antiarrhythmic effects .
    EHNA hydrochloride
  • HY-B1392S
    Esmolol-d7 hydrochloride

    		Isotope-Labeled Compounds Adrenergic Receptor Autophagy Mitophagy Cardiovascular Disease Endocrinology Cancer
    Esmolol-d7 hydrochloride is the deuterium labeled Esmolol hydrochloride (HY-B1392). Esmolol hydrochloride is an ultra-short-acting cardioselective β1-adrenergic blocker. Esmolol hydrochloride exerts its antiarrhythmic effect by activating Neurokinin 1 Receptoraldose reductase) and the production of advanced glycation end products and promoting fibroblast migration. Esmolol hydrochloride can be used to study cardiac diseases such as arrhythmias and diabetic foot ulcers .
    Esmolol-d7 hydrochloride
  • HY-B1392R
    Esmolol hydrochloride (Standard)

    		Reference Standards Adrenergic Receptor Autophagy Mitophagy Cardiovascular Disease Endocrinology Cancer
    Esmolol hydrochloride (Standard) is the analytical standard of Esmolol hydrochloride (HY-B1392).This product is intended for research and analytical applications. Esmolol hydrochloride is an ultra-short-acting cardioselective β1-adrenergic blocker. Esmolol hydrochloride exerts its antiarrhythmic effect by activating Neurokinin 1 Receptoraldose reductase and the production of advanced glycation end products and promoting fibroblast migration. Esmolol hydrochloride can be used to study cardiac diseases such as arrhythmias and diabetic foot ulcers .
    Esmolol hydrochloride (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: